It never made sense that HM3 patients who almost certainly develop acquired von Willebrand syndrome would need an antiplatelet agent and we finally have the data proving it!

When to suspect cardiac amyloidosis? Echo features: 🔹Nondilated LV with thickened walls 🔹E/A > 2 and E/e’ > 14 🔹Biatrial enlargement 🔹Valvular thickening 🔹Apical sparing strain pattern …and the following clinical features, 🖼️ via British Society of Echocardiography:

Patient with ACS found to have new AF. Something commonly overlooked is in Pioneer AF-PCI, rivaroxaban was reduced to 15 mg daily in pts otherwise indicated for 20 mg daily. Make things simple and use apixaban which was studied at the same dose as used in its landmark AF trial.

Clinical strategies for mitigating adverse events with GLP-1 medicines Beverly G. Tchang, MD #ADA2024 pubmed.ncbi.nlm.nih.gov/34775881/

If there was half as much enthusiasm about initiating spironolactone as there is about sacubitril/valsartan, the world would be a better place 😌

Hence my Antibiotic Stewardship for the 21st Century Lecture: slides

Analogous to LVAD ramp studies, a trial assessing RHC to guide optimal pacing rates for HFpEF may allow for further individualization of pacer settings beyond the algorithm used in MyPace jamanetwork.com/journals/jamac…

New: Either ACEi or ARB therapy protect against kidney failure in those with advanced CKD. Neither therapy provided a death benefit for those with late-stage CKD: ecs.page.link/SWNAD

🚨When it is a YES ✅ and not 🚫in DOACS 💊 👉🏻 J Am Coll Cardiol 2024;83:444-465.

If you think finerenone is good, just wait until you hear about this drug called spironolactone.

So that statistically significant ~1.5% reduction of a composite endpoint driven by the weakest of the endpoints in COLCOT was actually just noise? Who would have thought? #colchicine acc.org/Latest-in-Card…

A surrogate outcome does not mean a new age. This type of study leads to over prescribing based on a soft endpoint with financial detriment to the patient with no proven benefit in hard outcomes. Does the next drug that reduces BNP create a new age for heart failure?